| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.063 | 0.2 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.2 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.2 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |